The contract research organization said it has already used CRISPR/Cas9 editing in several customer projects and also plans to use it for internal R&D.
Researchers from both teams plan to continue to refine their findings toward creating simple PCR or other nucleic acid amplification-based assays.
The investment bank, which also set a 12-month price target of $5 for the company's shares, said it anticipates a growing footprint for the HTG EdgeSeq system.
The Center of Individualized Diagnostic aims to bring genomic-based cancer diagnostics to Saudi Arabia.
The company hopes to leverage NxGen's assets and relationships in the maternal-fetal medicine space to aid commercialization of its proteomic preterm birth test.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.
The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.
An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.
In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.